Li HG, Xie DR, Shen XM, Li HH, Zeng H, Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 2005; 11(10): 1445-1451 [PMID: 15770719 DOI: 10.3748/wjg.v11.i10.1445]
Corresponding Author of This Article
De-Rong Xie, Department of Oncology, Second Affiliated Hospital to Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China. xiederong@21cn.com
Article-Type of This Article
Liver Cancer
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2005; 11(10): 1445-1451 Published online Mar 14, 2005. doi: 10.3748/wjg.v11.i10.1445
Table 1 Expression of paxillin protein categorized by pathological variables.
Variables
Paxillin
P
-
+
Serum AFP level
≤25 ng/mL (n = 22)
13
9
0.604
>25 ng/mL (n = 29)
15
14
HBsAg
Positive (n = 16)
8
8
0.638
Negative (n = 35)
20
15
Microsatellite nodule
Absent (n = 31)
17
14
0.991
Present (n = 20)
11
9
Tumor size
≤3 cm (n = 18)
8
10
0.272
>3 cm (n = 33)
20
13
Cirrhosis
Absent (n = 36)
20
16
0.886
Present (n = 15)
8
7
Necrosis
Absent (n = 24)
13
11
0.922
Present (n = 27)
15
12
Portal vein thrombosis
Absent (n = 37)
24
13
0.021
Present (n = 14)
4
10
Differentiation
Well (n = 35)
24
11
0.004
Low (n = 16)
4
12
Extra-hepatic metastasis
Absent (n = 41)
26
15
0.014
Present (n = 10)
2
8
Table 2 Expression of syndecan-1 protein categorized by pathological variables.
Variables
Syndecan-1
P
-
+
Serum AFP level
≤25 ng/mL (n = 22)
8
14
0.28
>25 ng/mL (n = 29)
15
14
HBsAg
Positive (n = 16)
6
10
0.465
Negative (n = 35)
17
18
Microsatellite nodule
Absent (n = 31)
13
18
0.578
Present (n = 20)
10
10
Tumor size
≤3 cm (n = 18)
9
9
0.607
>3 cm (n = 33)
14
19
Cirrhosis
Absent (n = 36)
17
19
0.64
Present (n = 15)
6
9
Necrosis
Absent (n = 24)
10
14
0.646
Present (n = 27)
13
14
Portal vein thrombosis
Absent (n = 37)
15
22
0.292
Present (n = 14)
8
6
Differentiation
Well (n = 35)
10
25
0.001
Low (n = 16)
13
3
Extra-hepatic metastasis
Absent (n = 41)
15
26
0.014
Present (n = 10)
8
2
Table 3 Expression of EMMPRIN protein categorized by pathological variables.
Variables
EMMPRIN
P
-
+
Serum AFP level
≤25 ng/mL (n = 22)
12
10
0.242
>25 ng/mL (n = 29)
11
18
HBsAg
Positive (n = 16)
9
7
0.284
Negative (n = 35)
14
21
Microsatellite nodule
Absent (n = 31)
13
18
0.576
Present (n = 20)
10
10
Tumor size
≤3 cm (n = 18)
9
9
0.607
>3 cm (n = 33)
14
19
Cirrhosis
Absent (n = 36)
18
18
0.281
Present (n = 15)
5
10
Necrosis
Absent (n = 24)
11
13
0.992
Present (n = 27)
12
15
Portal vein thrombosis
Absent (n = 37)
15
22
0.292
Present (n = 14)
8
6
Differentiation
Well (n = 35)
16
19
0.897
Low (n = 16)
7
9
Extra-hepatic metastasis
Absent (n = 41)
19
22
0.721
Present (n = 10)
4
6
Table 4 Association between paxillin and syndecan-1 protein.
Paxillin
Syndecan-1
P
-
+
Negative
8
20
0.01
Positive
15
8
Table 5 Association between EMMPRIN and paxillin, syndecan-1 protein.
Paxillin
EMMPRIN
P
-
+
Negative
15
13
0.184
Positive
8
15
Syndecan-1
Negative
13
10
0.141
Positive
10
18
Citation: Li HG, Xie DR, Shen XM, Li HH, Zeng H, Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 2005; 11(10): 1445-1451